Truveta

Health-system-owned data company that aggregates de-identified electronic health records for research, with a genome project run with Regeneron and Illumina.

View on the globe

$320MEquity raised in 2025–20262025 $320M · 2026 — · 1 equity round
$415MEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 2 rounds from 13 Jul 2021 to 13 Jan 2025, $415M equity disclosed. Earlier rounds exist but are not sourced.13 Jul 2021: Funding round, $95M; 13 Jan 2025: Preferred equity financing, $320M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedest. 20202022202320242025Equity round13 Jan 2025 · Preferred equity financing · $320M13 Jul 2021 · Funding round · $95MVenture · $320MVenture · $95M
Funding history: 2 rounds from 13 Jul 2021 to 13 Jan 2025, $415M equity disclosed. Earlier rounds exist but are not sourced.13 Jul 2021: Funding round, $95M; 13 Jan 2025: Preferred equity financing, $320M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourced’202022202320242025Equity round13 Jan 2025 · Preferred equity financing · $320M13 Jul 2021 · Funding round · $95M$320M$95M

Funding history 2 rounds · 3 sources · newest first

Earlier rounds not yet sourced. Truveta was founded in 2020 and raised before 13 Jul 2021; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Preferred equity financing
    Amount$320M
    Post-money—
    ✓ Confirmed
    Also
    Regeneron, Illumina
    Note
    $320M of preferred equity from 17 health systems, Regeneron ($119.5M upfront) and Illumina ($20M), announced with the Truveta Genome Project; the company did not label the round (some outlets call it Series C). Valuation stated only as above $1B. Microsoft had made an earlier strategic investment (amount not disclosed).
    Sources
  2. Funding round
    Amount$95M
    Post-money—
    ◔ Reported
    Note
    Described only as new funding; round label, lead and participants not stated. The health-system members listed in the report were existing backers, not named as investors in this round.
    Sources
  3. Earlier rounds not yet sourced

Investors 2

  • Illumina
  • Regeneron

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Also in the Bellevue hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Truveta and its logo are trademarks of their owners, used here for identification only.